The cytokine interleukin-22 (IL-22) is an inhibitor of cellular stress. In HFD murine models, systemic IL-22 is efficacious to restore glucose tolerance, reduce circulating triglycerides and hepatic steatosis, and improve AST:ALT ratio, but is also associated with gut and skin toxicity. As an approach to maintain efficacy without skin/gut adverse effects we have developed a prototype IL-22-based bispecific biologic drug candidate (IL-22-ScFv) which is targeted towards the pancreas and liver. In mouse models of T2D and NAFLD/NASH twice-weekly subcutaneous administration of IL-22-ScFv provides numerous therapeutic and metabolic benefits. After IL-22-ScFv administration for four weeks in HFD mice random glucose, glucose tolerance and insulin tolerance were normalised (c.f. chow fed controls) . Significant reduction in hepatic steatosis was also seen, evidenced by liver weight, histology, oil-red-O, and (normalisation of) key lipogenic gene expression patterns. In both Thioacetamide/HFD and Choline Deficient L-Amino acid defined/HFD mice IL-22-ScFv administration significantly reduced hepatic fibrosis (Masson’s trichrome, picrosirius red, and normalisation of hepatic expression of Col1a1&2, Col3a1, Timp2, Mmp2 and Cd68) . Effective targeting of IL-22 to liver and pancreas was observed with minimal IL-22 exposure to gut and skin. Following four weeks administration of a range of doses of IL-22-ScFv no adverse effects were observed. Histological analysis of gut and skin showed no features of hyperproliferation, consistent with effective targeting of IL-22 to liver and pancreas. Mechanism of action of IL-22-ScFv was again shown to be reduction in cellular stress via IL-22 receptor mediated STAT3 phosphorylation.

In conclusion, liver/pancreas targeted IL-22 shows promise as a therapeutic approach to metabolic liver disease, with concomitant improvement in disorders of glucose homeostasis.


J. B. Prins: None. H. Sajiir: None. S. Keshvari: None. K. Wong: None. J. Lockett: Advisory Panel; Lilly Diabetes. M. Mcguckin: None. S. Z. Hasnain: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at